ELTP 8-K SEC Filing Analysis

Latest settled — T+5d

ELTP ▲ +8.33% at T+5d

NEUTRAL call ✓ call won +8.33% · α vs SPY +11.08% · entry $0.3600 → $0.3900

Next anchor: T+20d in 17d

Currently $0.3400 · -5.56% from $0.3600 entry

Entry anchored
Jun 1, 2026
via day open

T+1d

+11.11%

call +11.11% · α +10.97%

$0.4000

settled 11d ago

T+5d

+8.33%

call +8.33% · α +11.08%

$0.3900

settled 5d ago

T+20d

—

call — · α —

—

in 17d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Elite Pharmaceuticals announced it filed an Abbreviated New Drug Application (ANDA) with the FDA for a generic anticoagulant drug. The branded product has $26 billion in trailing twelve-month sales (IQVIA data) with no generic currently on the market, but the brand has unexpired patents and exclusivities that must be addressed before approval. This is an early-stage regulatory milestone with no guaranteed approval timeline or commercial outcome.

Actionable Insight

This is an early-stage pipeline event with no approval timeline or revenue guidance. Monitor for FDA acceptance of the ANDA, patent challenge updates, and any subsequent partnership or financing announcements. No immediate trading catalyst without further regulatory clarity.

Key Facts

Elite filed an ANDA for a generic version of an undisclosed anticoagulant drug
Branded product sales were $26 billion for the twelve months ending March 2026 per IQVIA
No generic product is currently on the market for this drug
The brand has unexpired patents and exclusivities listed in the FDA Orange Book
FDA approval and commercialization depend on successful filing, FDA approval, and addressing patents/exclusivities

Financial Impact

No financial figures provided beyond the $26 billion branded market size; Elite's revenue, costs, and potential market share are not disclosed

revenuedilution

Risk Factors

FDA may not accept or approve the ANDA
Unexpired brand patents and exclusivities could block launch for years or require costly litigation
Elite may need additional capital to fund development and commercialization
Generic anticoagulant market may face pricing pressure and competition

Market Snapshot

Exchange

OTC

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001493152-26-026519
Exhibit: ex99-1.htm	0001493152-26-026519
Document: 0001493152-26-026519-index-headers.html	0001493152-26-026519
Document: 0001493152-26-026519-index.html	0001493152-26-026519
Document: 0001493152-26-026519.txt	0001493152-26-026519

2 reports for ELTP

T+1T+5T+20T+60

Filters

Reports for ELTP — sortable, filterable
	Type				Now
Jun 1, 2026 11d ago	8-K NEUTRAL ★ 4/10	$0.3600 $0.3900	▲ +8.33%	▲ +11.08%	$0.3400 (−5.56%)
Apr 2, 2026 10w ago	8-K NEUTRAL ★ 4/10	$0.3800 $0.3800	· 0.00%	▼ −3.62%	$0.3400 (−10.53%)

US Market Status

Market Closed — Opens Mon (52h 14m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access